Browse by Poster Presenter

Type here to filter the list

A
A. Sanders, Mathijs

Erasmus University Medical Center, Rotterdam
(P 231) COMPREHENSIVE MOLECULAR PROFILING OF FOLLICULAR DENDRITIC CELL SARCOMA
Mathijs A. Sanders
Favorite
A.abdeltwab, asmaa

assiot university
(P 067) CLINICAL-EPIDEMIOLOGICAL AND TREATMENT FACTORS IMPACT ON SURVIVAL IN EGYPTIAN PATIENTS WITH HEAD AND NECK SARCOMA: A RETROSPECTIVE CASE-SERIES ANALYSIS
asmaa A.abdeltwab
Favorite
Aaroe, Ashley

MD Anderson Cancer Center
(P 013) A PHASE 2 TRIAL OF CETUXIMAB FOR PATIENTS WITH LOCALLY ADVANCED/METASTATIC CHORDOMA
Ashley Aaroe
Favorite
Abar, Bijan

Duke
(P 034) REGIONAL ANESTHESIA IMPROVES METASTASIS FREE SURVIVAL AFTER SURGICAL RESECTION OF BONE SARCOMAS
Bijan Abar
Favorite
Abbott, Annalise

University of Calgary
(P 286) INDICATIONS AND LONGEVITY OF ENDOPROSTHETIC RECONSTRUCTIONS FOR PATIENTS WITH METASTATIC BONE DISEASE
Annalise Abbott
Favorite
Abdelhameed, Donia

Assiut University
(P 067) CLINICAL-EPIDEMIOLOGICAL AND TREATMENT FACTORS IMPACT ON SURVIVAL IN EGYPTIAN PATIENTS WITH HEAD AND NECK SARCOMA: A RETROSPECTIVE CASE-SERIES ANALYSIS
Donia Abdelhameed
Favorite
Abdul Razak, Albiruni Ryan

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto; Department of Medical Oncology, Mount Sinai Hospital
(P 068) CLINICO-DEMOGRAPHIC CHARACTERISTICS AND OUTCOMES OF RADIATION-INDUCED SARCOMAS: A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Albiruni Ryan Abdul Razak
Favorite
(P 116) SAFETY AND EFFICACY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: LONG-TERM PHASE 1 UPDATE
Albiruni Ryan Abdul Razak
Favorite
(P 165) REAL- WORLD EXPERIENCE OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH RECURRENT BONE TUMOURS (BT): A CANSARCC STUDY
Albiruni Ryan Abdul Razak
Favorite
(P 191) SYNERGISTIC ACTIVITY OF PARP INHIBITORS IN COMBINATION WITH STANDARD CHEMOTHERAPY IN LEIOMYOSARCOMA
Albiruni Ryan Abdul Razak
Favorite
(P 290) OSTEOSARCOMA OF THE HEAD AND NECK (HN) IN ADULTS: A CANSARCC STUDY
Albiruni Ryan Abdul Razak
Favorite
Abellan, M Dolores

HCU VIRGEN ARRIXACA
(P 318) NEOADJUVANT CHEMORADIOTHERAPY IN ADVANCED SOFT TISSUE SARCOMA. UPDATED NASAR STUDY
M Dolores Abellan
Favorite
Abraham, Alan

Beatson West of Scotland Cancer Centre
(P 073) EVALUATING DISTRESS AND THE PATIENT EXPERIENCE OF SARCOMA PATIENTS IN THE WEST OF SCOTLAND
Alan Abraham
Favorite
Abraham, Jim

Caris Life Science
(P 234) DNA DAMAGE RESPONSE PATHWAYS IN SYNOVIAL SARCOMA
Jim Abraham
Favorite
Abraham, John

Rothman Institute
(P 095) A COLLABORATIVE MULTIDISCIPLINARY APPROACH MAY LEAD TO ENHANCED CLINICAL OUTCOMES AND QUALITY OF CARE FOR PATIENTS WITH DIFFUSE TGCT
John Abraham
Favorite
Abu Quider, Abed
(P 257) SELECTIVE INTRA-ARTERIAL DOXORUBICIN-ELUTING EMBOLIZATION FOR DESMOID FIBROMATOSIS: A COMBINED PROSPECTIVE AND RETROSPECTIVE STUDY
Abed Abu Quider
Favorite
Acem, Ibtissam

Erasmus MC Cancer Institute
(P 051) NON-INVASIVE DETECTION OF SOFT TISSUE SARCOMA USING VOLATILE ORGANIC COMPOUNDS IN EXHALED BREATH: A PILOT STUDY
Ibtissam Acem
Favorite
Adam, Ammar

Foghorn Therapeutics
(P 187) PRECLINICAL VALIDATION OF TARGET ENGAGEMENT ASSAYS AND INVESTIGATION OF MECHANISTIC IMPACTS OF FHD-609, A CLINICAL-STAGE BRD9 DEGRADER BEING DEVELOPED FOR THE TREATMENT OF SYNOVIAL SARCOMA
Ammar Adam
Favorite
ADAM, JULIEN

INSTITUT GUSTAVE ROUSSY
(P 217) PLANNED MARGINAL (R1) RESECTION IN PRIMARY RETROPERITONEAL SARCOMAS: RETROSPECTIVE SERIES ON 168 PATIENTS FROM A NATIONAL SPECIALIZED REFERRAL CENTER
JULIEN ADAM
Favorite
Agaimy, Abbas

University Hospital Erlangen
(P 231) COMPREHENSIVE MOLECULAR PROFILING OF FOLLICULAR DENDRITIC CELL SARCOMA
Abbas Agaimy
Favorite
Aggenbach, Laura

The Royal Marsden Hospital
(P 085) RADIATION ASSOCIATED ANGIOSARCOMAS OF THE BREAST: MULTIFOCALITY WARRANTS AGGRESSIVE ONCOLOGICAL STRATEGY
Laura Aggenbach
Favorite
Aggerholm-Pedersen, Ninna

Department of Oncology, Aarhus University Hospital
(P 120) THE DIAGNOSTIC AND PROGNOSTIC VALUE OF PLASMA SMALL EXTRACELLULAR VESICLES PHENOTYPE IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOUR
Ninna Aggerholm-Pedersen
Favorite
Aghababazadeh, Masoumeh

McGill University
(P 232) DECIPHERING METASTASIS MAINTENANCE AND CHEMO RESISTANCE EVENTS IN CIC-DUX4 SARCOMA
Masoumeh Aghababazadeh
Favorite
Agresta, Samuel

Foghorn Therapeutics
(P 187) PRECLINICAL VALIDATION OF TARGET ENGAGEMENT ASSAYS AND INVESTIGATION OF MECHANISTIC IMPACTS OF FHD-609, A CLINICAL-STAGE BRD9 DEGRADER BEING DEVELOPED FOR THE TREATMENT OF SYNOVIAL SARCOMA
Samuel Agresta
Favorite
Aguilar Torres, Ileana

Stanford University
(P 130) MONITORING SOFT TISSUE SARCOMA RESPONSE TO IMMUNE CHECKPOINT INHIBITION AND CRYOTHERAPY WITH CIRCULATING TUMOR DNA ANALYSIS
Ileana Aguilar Torres
Favorite
Agulnik, Mark

City of Hope Comprehensive Cancer Center
(P 268) INITIAL RESULTS OF PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS (DT)
Mark Agulnik
Favorite
(P 312) A PHASE 1/2 STUDY OF CFT8634, A NOVEL BIFUNCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Mark Agulnik
Favorite
Ahari, Amir

Sarcoma Oncology Center
(P 122) AN UPDATE ON TNT: A PHASE-2 STUDY OF THE EFFICACY AND SAFETY OF TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN IN ADVANCED SARCOMA
Amir Ahari
Favorite
(P 123) COMPLETE RESPONSES WITH SAINT PROTOCOL: A PHASE 2 STUDY USING SAFE AMOUNTS OF IPILIMUMAB, NIVOLUMAB, AND TRABECTEDIN IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (NCT03138161)
Amir Ahari
Favorite
(P 126) GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN, NIVOLUMAB, AND DOCETAXEL AS SECOND/THIRD-LINE THERAPY FOR ADVANCED SARCOMA (NCT04535713)
Amir Ahari
Favorite
(P 132) PHASE 1/2 COMBINATION REGIMEN WITH IPILIMUMAB (I), NIVOLUMAB (N), AND TRABECTEDIN (T) AS FIRST-LINE THERAPY FOR ADVANCED LEIOMYOSARCOMA [NCT03138161]
Amir Ahari
Favorite
(P 133) PHASE 2 COMBINATION REGIMEN WITH TALIMOGENE LAHERPAREPVEC (TVEC), NIVOLUMAB AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA [NCT# 03886311]
Amir Ahari
Favorite
(P 137) SAINT: FIVE YEAR RESULTS OF A PHASE 2 TRIAL USING IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) FOR PREVIOUSLY UNTREATED ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Amir Ahari
Favorite
(P 138) SUSTAINED REMISSION/DISEASE CONTROL USING AUTOLOGOUS ENHANCED NATURAL KILLER CELLS PLUS AN IMMUNE CHECKPOINT INHIBITOR AS TREATMENT FOR RARE CHEMOTHERAPY-RESISTANT ADVANCED SOFT TISSUE SARCOMAS
Amir Ahari
Favorite
(P 321) PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM FOR ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MAXIMUM TOLERATED DOSE/RECOMMENDED PHASE 2 DOSE.
Amir Ahari
Favorite
Ahmed, Safia

Mayo Clinic
(P 020) DEFINITIVE RADIATION THERAPY FOR EWING SARCOMA: TREATMENT AND TOXICITY OUTCOMES IN PATIENTS TREATED WITH DOSE ESCALATION APPROACHES
Safia Ahmed
Favorite
(P 023) FACTORS ASSOCIATED WITH LOCAL CONTROL AND SURVIVAL IN LOCALIZED EWING SARCOMA PATIENTS TREATED WITH SURGERY ON AEWS1031: A REPORT FROM THE CHILDRENS ONCOLOGY GROUP
Safia Ahmed
Favorite
(P 201) LOCAL CONTROL AND SURVIVAL OUTCOMES IN PEDIATRIC NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
Safia Ahmed
Favorite
(P 207) SPATIALLY FRACTIONATED RADIATION THERAPY IN SARCOMAS: THE MAYO CLINIC EXPERIENCE
Safia Ahmed
Favorite
Ahrens, Marit

Medical Clinic II, University Hospital Frankfurt
(P 176) FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA
Marit Ahrens
Favorite
Ahrens, Will

Atrium Health/Levine Cancer Institute
(P 261) CLINICAL FEATURES AND TREATMENT OUTCOMES OF PATIENTS WITH DESMOID TUMORS: A LARGE SINGLE INSTITUTION RETROSPECTIVE SERIES
Will Ahrens
Favorite
Aiba, Hisaki

Department of Medical Oncology, National Cancer Center Hospital
(P 147) ANALYSIS OF INFLAMMATORY BIOMARKERS AS PREDICTORS OF TREATMENT EFFICACY IN SOFT TISSUE SARCOMA TREATED WITH TRABECTEDIN
Hisaki Aiba
Favorite
(P 150) CLINICAL CHARACTERISTICS OF PRIMARY CUTANEOUS AND SUBCUTANEOUS EWING SARCOMA FAMILY OF TUMORS
Hisaki Aiba
Favorite
Aizawa, Toshimi

Tohoku University School of Medicine
(P 091) THE PROGNOSIS OF PULMONARY METASTASIS AFTER THE SURGERY FOR PRIMARY LESION IN ELDERLY HIGH-GRADE SARCOMA PATIENTS
Toshimi Aizawa
Favorite
(P 209) THE OUTCOME OF R1 EXCISION COMBINED WITH ADJUVANT RADIOTHERAPY FOR SOFT TISSUE SARCOMA IN ELDERLY PATIENTS
Toshimi Aizawa
Favorite
Akdemir, Kadir

MD Anderson Cancer Center
(P 013) A PHASE 2 TRIAL OF CETUXIMAB FOR PATIENTS WITH LOCALLY ADVANCED/METASTATIC CHORDOMA
Kadir Akdemir
Favorite
Al Shihabi, Ahmad

University of California, Los Angeles
(P 183) OSTEOSARCOMA ORGANOIDS RECAPITULATE TUMOR CHARACTERISTICS AND MAINTAIN HETEROGENEITY
Ahmad Al Shihabi
Favorite
(P 184) PAN-SARCOMA ORGANOID SCREENING PIPELINE
Ahmad Al Shihabi
Favorite
Al-Awar, Rima

Ontario Institute for Cancer Research
(P 191) SYNERGISTIC ACTIVITY OF PARP INHIBITORS IN COMBINATION WITH STANDARD CHEMOTHERAPY IN LEIOMYOSARCOMA
Rima Al-Awar
Favorite
Albarrán-Fernández, Víctor

Department of Medical Oncology, Ramón y Cajal University Hospital
(P 157) MOLECULAR SCREENING OF ADVANCED SARCOMAS THROUGH NEXT-GENERATION SEQUENCING IN A TERTIARY UNIVERSITY HOSPITAL
Víctor Albarrán-Fernández
Favorite
Albert, Catherine

Seattle Children’s Hospital, University of Washington, Fred Hutchinson Cancer Research Center
(P 310) TUMOR REVIEW BOARD FOR OSTEOSARCOMA (TURBO): BIMONTHLY, MULTI-INSTITUTIONAL, MULTIDISCIPLINARY VIRTUAL TUMOR BOARD FOR OSTEOSARCOMA
Catherine Albert
Favorite
Albert-Thananayagam, Marie

Centre Oscar Lambret
(P 080) INTRACRANIAL SOLITARY FIBROUS TUMOUR/HEMANGIOPERICYTOMA MANAGEMENT: A FRENCH MULTICENTRE RETROSPECTIVE STUDY
Marie Albert-Thananayagam
Favorite
Albright, Eric

Indiana University School of Medicine/Riley Hospital for Children
(P 226) ASSESSING PREDICTIVE VALUE OF RNA-SEQ OF B4GALNT1 AND ST8SIA1 AS BIOMARKERS OF GD2 EXPRESSION IN PEDIATRIC SARCOMAS
Eric Albright
Favorite
Alcindor, Thierry

Dana-Farber Cancer Institute
(P 092) THE SARCOMA-SPECIFIC QUALITY OF LIFE STUDY (SARC-QOL): IDENTIFYING KEY DOMAINS OF HEALTH-RELATED QUALITY OF LIFE IN ADULT PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMA
Thierry Alcindor
Favorite
(P 102) EFFICACY AND SAFETY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: PHASE 2 EXPANSION
Thierry Alcindor
Favorite
(P 165) REAL- WORLD EXPERIENCE OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH RECURRENT BONE TUMOURS (BT): A CANSARCC STUDY
Thierry Alcindor
Favorite
Alder, Kareme

Mayo Clinic
(P 291) OUTCOME OF MULTIDISCIPLINARY TREATMENT OF MERKEL CELL CARCINOMA OF THE UPPER EXTREMITY
Kareme Alder
Favorite
Aleshin, Alexey

Natera, Inc
(P 047) FEASIBILITY OF A PERSONALIZED AND TUMOR-INFORMED CT-DNA ASSAY IN PATIENTS WITH LEIOMYOSARCOMA
Alexey Aleshin
Favorite
Alexandrow, Mark

Moffitt Cancer Center
(P 019) COUMERMYCIN-A1 (CA1) IDENTIFIED AS A FIRST-IN-CLASS CDC45-MCM-GINS HELICASE INHIBITOR OFFERING THERAPEUTIC POTENTIAL FOR OSTEOSARCOMA TREATMENT
Mark Alexandrow
Favorite
Alexe, Gabriela

Dana Farber
(P 036) STAG2 LOSS ENCHANCES SENSITIVITY TO DNA DAMAGE YET REDUCES DNA DAMAGE-INDUCED INFLAMMATION IN EWING SARCOMA
Gabriela Alexe
Favorite
Aliaga, Alfonso

Hospital Universitario Virgen de la Arrixaca
(P 219) PROGNOSTIC VALUE OF HEMATOLOGICAL MARKERS IN LEIOMYOSARCOMA
Alfonso Aliaga
Favorite
(P 281) CUTANEOUS SARCOMA: CASE SERIES DESCRIPTION AND ANALYSIS OF FACTORS RELATED TO AN UNFAVORABLE EVOLUTION
Alfonso Aliaga
Favorite
Ali, Amro

C4 Therapeutics
(P 312) A PHASE 1/2 STUDY OF CFT8634, A NOVEL BIFUNCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Amro Ali
Favorite
Al-Ibraheemi, Alyaa

Department of Pathology, Boston Children’s Hospital
(P 010) SPECTRUM OF EWING-LIKE FUSIONS AND SECONDARY GENOMIC ALTERATIONS FROM A LARGE NEXT GENERATION SEQUENCING (NGS) COMPREHENSIVE GENOMIC PROFILING (CGP) DATABASE
Alyaa Al-Ibraheemi
Favorite
(P 239) FGFR IS A RELEVANT MOLECULAR TARGET IN PEDIATRIC AND AYA SARCOMAS
Alyaa Al-Ibraheemi
Favorite
Allajbej, Albina

Fondazione IRCCS Istituto Nazionale Dei Tumori
(P 145) A RETROSPECTIVE CASE SERIES ANALYSIS OF 22 RHABDOMYOSARCOMA PATIENTS WITH SPINDLE-CELL/SCLEROSING MORPHOLOGY
Albina Allajbej
Favorite
(P 203) MULTIDISCIPLINARY APPROACH OF ADVANCED-STAGE ALVEOLAR RHABDOMYOSARCOMA OF THE MAXILLARY SINUS IN ADULTS: A CASE REPORT
Albina Allajbej
Favorite
Allen, Bryan

University of Iowa Hospitals & Clinics
(P 159) NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Bryan Allen
Favorite
(P 160) NEOADJUVANT PHARMACOLOGICAL ASCORBATE WITH CONCURRENT RADIATION IN LOCALLY ADVANCED SOFT-TISSUE SARCOMA OF EXTREMITY/TRUNK AND RETROPERITONEUM
Bryan Allen
Favorite
Allen-Rhoades, Wendy

Mayo Clinic
(P 020) DEFINITIVE RADIATION THERAPY FOR EWING SARCOMA: TREATMENT AND TOXICITY OUTCOMES IN PATIENTS TREATED WITH DOSE ESCALATION APPROACHES
Wendy Allen-Rhoades
Favorite
Allen-Rhoades, Wendy

Mayo Clinic
(P 201) LOCAL CONTROL AND SURVIVAL OUTCOMES IN PEDIATRIC NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
Wendy Allen-Rhoades
Favorite
Almond, Max

Department of Surgical Oncology, University Hospitals Birmingham
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Max Almond
Favorite
Alonso, Jose Luis

HCU VIRGEN ARRIXACA
(P 318) NEOADJUVANT CHEMORADIOTHERAPY IN ADVANCED SOFT TISSUE SARCOMA. UPDATED NASAR STUDY
Jose Luis Alonso
Favorite
Alvarez-Breckenridge, Christopher

MD Anderson Cancer Center
(P 013) A PHASE 2 TRIAL OF CETUXIMAB FOR PATIENTS WITH LOCALLY ADVANCED/METASTATIC CHORDOMA
Christopher Alvarez-Breckenridge
Favorite
Alvarez, Rosa

HU Gregorio Marañón
(P 161) PALBOSARC: A PHASE II TRIAL OF PALBOCICLIB IN ADVANCED SARCOMA OVEREXPRESSING CDK4 GENE EXCLUDING DEDIFFERENTIATED LIPOSARCOMA (DD LPS): A STUDY FROM THE SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS).
Rosa Alvarez
Favorite
(P 225) TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Rosa Alvarez
Favorite
Alvi, Saima

Saskatchewan Health Authority
(P 165) REAL- WORLD EXPERIENCE OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH RECURRENT BONE TUMOURS (BT): A CANSARCC STUDY
Saima Alvi
Favorite
Amankwah, Ernest

Johns Hopkins All Children's Hospital
(P 305) THE INCIDENCE OF THROMBOEMBOLIC EVENTS DURING HOSPITALIZATIONS FOLLOWING SURGICAL RESECTION OF LOWER EXTREMITY SARCOMAS IN CHILDREN: UTILIZING THE PEDIATRIC HEALTH INFORMATION SYSTEM (PHIS) DATABASE
Ernest Amankwah
Favorite
Amary, Fernanda

Royal National Orthopaedic Hospital NHS Trust
(P 011) TACKLE A RARE SARCOMA THROUGH A COLLABORATIVE APPROACH
Fernanda Amary
Favorite
(P 252) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA RESEARCH INITIATIVE
Fernanda Amary
Favorite
Amatruda, James

Children's Hospital Los Angeles
(P 045) DETECTION OF CELL-FREE TUMOR DNA IN PATIENTS WITH NEWLY DIAGNOSED PEDIATRIC BONE AND SOFT TISSUE SARCOMAS
James Amatruda
Favorite
Amini, Behrang

The University of Texas MD Anderson Cancer Center
(P 013) A PHASE 2 TRIAL OF CETUXIMAB FOR PATIENTS WITH LOCALLY ADVANCED/METASTATIC CHORDOMA
Behrang Amini
Favorite
Anazodo, Antoinette
(P 257) SELECTIVE INTRA-ARTERIAL DOXORUBICIN-ELUTING EMBOLIZATION FOR DESMOID FIBROMATOSIS: A COMBINED PROSPECTIVE AND RETROSPECTIVE STUDY
Antoinette Anazodo
Favorite
Andelkovic, Vladimir

Princess Alexandra Hospital and Icon Cancer Centre,
(P 268) INITIAL RESULTS OF PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS (DT)
Vladimir Andelkovic
Favorite
Anderson, Carryn

University of Iowa Hospitals & Clinics
(P 159) NEOADJUVANT INTRATUMORAL HIGH DOSE TALIMOGENE LAHERPAREPVEC (TVEC) WITH CONCURRENT RADIATION IN HIGH-RISK EXTREMITY AND TRUNK SOFT-TISSUE SARCOMAS
Carryn Anderson
Favorite
(P 160) NEOADJUVANT PHARMACOLOGICAL ASCORBATE WITH CONCURRENT RADIATION IN LOCALLY ADVANCED SOFT-TISSUE SARCOMA OF EXTREMITY/TRUNK AND RETROPERITONEUM
Carryn Anderson
Favorite
Anderson, Colin

Levine Cancer Institute
(P 261) CLINICAL FEATURES AND TREATMENT OUTCOMES OF PATIENTS WITH DESMOID TUMORS: A LARGE SINGLE INSTITUTION RETROSPECTIVE SERIES
Colin Anderson
Favorite
Anderson, Megan

Dana-Farber Cancer Institute
(P 239) FGFR IS A RELEVANT MOLECULAR TARGET IN PEDIATRIC AND AYA SARCOMAS
Megan Anderson
Favorite
Anderson, Peter

Cleveland Clinic
(P 249) SARCOMA GENE FUSION BREAKPOINTS: NON-RANDOM EVENT PATTERNS IN SARCOMAS WITH GENE FUSIONS INCLUDING EWING SARCOMA, DSRCT, RHABDOMYOSARCOMA, SYNOVIAL SARCOMA, CCNB3-BCOR, AND CIC-DUX
Peter Anderson
Favorite
(P 310) TUMOR REVIEW BOARD FOR OSTEOSARCOMA (TURBO): BIMONTHLY, MULTI-INSTITUTIONAL, MULTIDISCIPLINARY VIRTUAL TUMOR BOARD FOR OSTEOSARCOMA
Peter Anderson
Favorite
(P 311) VIRTUAL VISITS FOR SARCOMAS AND OTHER RARE CANCERS INCLUDING DESMOIDS: THE EVOLUTION OF INFORMATION AND EDUCATIONAL OPPORTUNITIES TO IMPOVE HEALTH: 2017-2022
Peter Anderson
Favorite
Andor, Tom

Cogent Biosciences
(P 320) PEAK STUDY: A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Tom Andor
Favorite
Andree Tellez, Walter

Sarcoma oncolgy
(P 132) PHASE 1/2 COMBINATION REGIMEN WITH IPILIMUMAB (I), NIVOLUMAB (N), AND TRABECTEDIN (T) AS FIRST-LINE THERAPY FOR ADVANCED LEIOMYOSARCOMA [NCT03138161]
Walter Andree Tellez
Favorite
Andrews, Carol

University of Pittsburgh Medical Center
(P 087) RATING THE EFFICACY OF DIAGNOSTIC IMAGING STUDIES PERFORMED FOR THE WORK-UP OF MUSCULOSKELETAL MASSES
Carol Andrews
Favorite
Andrianov, Vasily

Inhibrx, Inc
(P 041) UPDATED EFFICACY AND SAFETY OF THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 IN PATIENTS WITH CHONDROSARCOMA: DATA FROM THE PHASE 1 EXPANSION COHORTS
Vasily Andrianov
Favorite
(P 317) INBRX-109 IN EWING SARCOMA: PRECLINICAL RATIONALE FOR INITIATION OF A PHASE 1 CHEMOTHERAPY COMBINATION EXPANSION COHORT
Vasily Andrianov
Favorite
Andrulis, Irene

Mount Sinai Hospital
(P 180) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Irene Andrulis
Favorite
(P 233) DETERMINING THE CONTRIBUTIONS OF PD-L1 AND STAT1 TO THE UPS ANTI-TUMOR MICROENVIRONMENT
Irene Andrulis
Favorite
Angeles, Christina

University of Michigan
(P 139) T-CELL PROFILING IN HIGH GRADE SARCOMAS
Christina Angeles
Favorite
Angelino, M. J.

Department of Surgery, Leiden University Medical Center
(P 109) NOVEL CANDIDATE BIOMARKERS FOR FLUORESCENCE IMAGE-GUIDED SURGERY IN GASTROINTESTINAL STROMAL TUMORS
M. J. Angelino
Favorite
Angus, Steve

Indiana University
(P 192) TARGETING PI3K/MTOR MITIGATES RESISTANCE TO CDK4/6 INHIBITION IN RB-PROFICIENT PEDIATRIC AND AYA OSTEOSARCOMAS
Steve Angus
Favorite
Annett, Alva

Department of Human Genetics, McGill University
(P 022) EZHIP ECTOPIC EXPRESSION AND ITS ROLE IN OSTEOSARCOMA PATHOGENESIS
Alva Annett
Favorite
Annett, Alva

Research Institute of the McGill University Health Centre
(P 030) OSTEOSARCOMA PATIENT-DERIVED-XENOGRAFTS A RELEVANT MODEL TO STUDY CHEMOTHERAPEUTIC AND METASTATIC EVENTS
Alva Annett
Favorite
Antonakos, Brandon

Foghorn Therapeutics
(P 187) PRECLINICAL VALIDATION OF TARGET ENGAGEMENT ASSAYS AND INVESTIGATION OF MECHANISTIC IMPACTS OF FHD-609, A CLINICAL-STAGE BRD9 DEGRADER BEING DEVELOPED FOR THE TREATMENT OF SYNOVIAL SARCOMA
Brandon Antonakos
Favorite
Antonescu, Cristina

MSKCC
(P 241) INVESTIGATING THE EVOLUTION OF CELL STATES IN UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING A GENETICALLY ENGINEERED MOUSE MODEL
Cristina Antonescu
Favorite
Anton, Ismael

Hospital insular gran canaria
(P 119) SURGICAL MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOURS SARCOMATOSIS (GISTOSIS). A RETROSPECTIVE MULTI-INSTITUTIONAL STUDY
Ismael Anton
Favorite
Apollonio, Giulia

University of Milan
(P 145) A RETROSPECTIVE CASE SERIES ANALYSIS OF 22 RHABDOMYOSARCOMA PATIENTS WITH SPINDLE-CELL/SCLEROSING MORPHOLOGY
Giulia Apollonio
Favorite
(P 203) MULTIDISCIPLINARY APPROACH OF ADVANCED-STAGE ALVEOLAR RHABDOMYOSARCOMA OF THE MAXILLARY SINUS IN ADULTS: A CASE REPORT
Giulia Apollonio
Favorite
Arakaki, Motoko

Department of Medical Oncology, National Cancer Center Hospital
(P 147) ANALYSIS OF INFLAMMATORY BIOMARKERS AS PREDICTORS OF TREATMENT EFFICACY IN SOFT TISSUE SARCOMA TREATED WITH TRABECTEDIN
Motoko Arakaki
Favorite
Arakawa, Ayumi

Department of Pediatric Oncology, National Cancer Center Hospital
(P 150) CLINICAL CHARACTERISTICS OF PRIMARY CUTANEOUS AND SUBCUTANEOUS EWING SARCOMA FAMILY OF TUMORS
Ayumi Arakawa
Favorite
Arani, Akash

Georgia Institute of Technology, School of Biological Sciences
(P 090) TEN-YEAR INCIDENCE AND MORTALITY OF SOFT TISSUE SARCOMAS IN THE NATIONAL CANCER CENTRE SINGAPORE, FROM 2012 TO 2021
Akash Arani
Favorite
Arjona, Alvaro

Hospital universitario reina Sofía
(P 119) SURGICAL MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOURS SARCOMATOSIS (GISTOSIS). A RETROSPECTIVE MULTI-INSTITUTIONAL STUDY
Alvaro Arjona
Favorite
Arndt, Carola

Mayo Alix School of Medicine
(P 155) LATE EVENTS OCCURRING AFTER 5 YEARS IN PEDIATRIC RHABDOMYOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Carola Arndt
Favorite
Arora, Arsha

University of Miami
(P 263) COMPARATIVE EFFECTIVENESS OF SYSTEMIC TREATMENTS IN DESMOID TUMORS
Arsha Arora
Favorite
Arrighetti, Noemi

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 170) ANTITUMOR ACTIVITY OF TAZEMETOSTAT AND DOXORUBICIN COMBINATION ON PATIENT-DERIVED PRECLINICAL MODELS OF EPITHELIOID SARCOMA
Noemi Arrighetti
Favorite
Arslan, Bulent

Rush University Medical Center
(P 032) PLEURAL RELAPSE OF OSTEOSARCOMA AFTER TALC PLEURODESIS
Bulent Arslan
Favorite
Arthur, Amani

Institute of Cancer Research
(P 061) UNRAVELLING THE HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT IN STS USING QUANTITATIVE MRI
Amani Arthur
Favorite
Artigas, Vicente

Dpt. de cirugía
(P 225) TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Vicente Artigas
Favorite
Arvis, Pierre

Bayer Pharmaceuticals
(P 107) LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Pierre Arvis
Favorite
Asaftei, Sebastian Dorin

Paediatric Onco-Haematology Division, Regina Margherita Children’s Hospital, City of Health and Science of Turin and Department of Public Health and Paediatrics, University of Turin
(P 016) ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Sebastian Dorin Asaftei
Favorite
(P 029) MOLECULAR CHARACTERIZATION OF OSTEOSARCOMA AND EWING SARCOMA IN PEDIATRIC PATIENTS REVEALS NOVEL RNA-BASED INTERVENTION POINTS.
Sebastian Dorin Asaftei
Favorite
Asare, Bernice

The Royal Marsden NHS Foundation Trust
(P 152) FINAL RESULTS OF GEMMK: A PHASE I TRIAL OF GEMCITABINE AND PEMBROLIZUMAB IN PATIENTS WITH LEIOMYOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Bernice Asare
Favorite
Ashman, Jonathan

Department of Radiation Oncology, Mayo Clinic
(P 202) LONG-TERM EXPERIENCE WITH INTRAOPERATIVE ELECTRON RADIATION THERAPY BOOST IN EXTREMITY SARCOMA
Jonathan Ashman
Favorite
Ashok, Arya

Tempus Labs
(P 039) THE GENOMIC AND IMMUNE LANDSCAPE OF OSTEOSARCOMA
Arya Ashok
Favorite
Ash, SHifra
(P 257) SELECTIVE INTRA-ARTERIAL DOXORUBICIN-ELUTING EMBOLIZATION FOR DESMOID FIBROMATOSIS: A COMBINED PROSPECTIVE AND RETROSPECTIVE STUDY
SHifra Ash
Favorite
atef, Doaa

Ain Shams university
(P 067) CLINICAL-EPIDEMIOLOGICAL AND TREATMENT FACTORS IMPACT ON SURVIVAL IN EGYPTIAN PATIENTS WITH HEAD AND NECK SARCOMA: A RETROSPECTIVE CASE-SERIES ANALYSIS
Doaa atef
Favorite
Atkinson, Thomas

Memorial Sloan Kettering Cancer Center
(P 04) EXPERT PANEL REVIEW OF THE PRO-AYA: PARTIENT-REPORTED OUTCOMES FOR ADOLESCENTS AND YOUNG ADULTS WITH CANCER
Thomas Atkinson
Favorite
Attia, Steven

Mayo Clinic
(P 312) A PHASE 1/2 STUDY OF CFT8634, A NOVEL BIFUNCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Steven Attia
Favorite
Augustin, Marinela

Paracelsus Medical University
(P 231) COMPREHENSIVE MOLECULAR PROFILING OF FOLLICULAR DENDRITIC CELL SARCOMA
Marinela Augustin
Favorite
Avilés, Pablo

Research Department, PharmaMar S.A.
(P 185) PHARMACOLOGICAL INHIBITION OF GLYOXALASE-1 AS NOVEL THERAPEUTIC STRATEGY TO POTENTIATE TRABECTEDIN ANTI-TUMOR EFFECT IN SOFT TISSUE SARCOMA PRECLINICAL MODELS
Pablo Avilés
Favorite
Avutu, Viswatej

Memorial Sloan Kettering Cancer Center
(P 04) EXPERT PANEL REVIEW OF THE PRO-AYA: PARTIENT-REPORTED OUTCOMES FOR ADOLESCENTS AND YOUNG ADULTS WITH CANCER
Viswatej Avutu
Favorite
(P 134) PHASE II STUDY OF RUCAPARIB AND NIVOLUMAB IN PATIENTS WITH LEIOMYOSARCOMA
Viswatej Avutu
Favorite
(P 144) A PHASE 1/2 DOSE ESCALATION/EXPANSION STUDY OF ZN-C3 PLUS GEMCITABINE IN RELAPSED/REFRACTORY OSTEOSARCOMA
Viswatej Avutu
Favorite
(P 307) ADOLESCENT AND YOUNG ADULT SARCOMA TREATMENT HARMONIZATION: AYA MAP FOR OSTEOSARCOMA
Viswatej Avutu
Favorite